Trial Profile
A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge (CAC)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cilomilast (Primary) ; Dexamethasone
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Alcon
- 09 Jun 2014 New trial record